Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
7496
Tickers With News
507
Showing Now
49
Top Ticker
TSLA
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on X.com by @tomicki. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $188.66 as of June 1st. VEEV’s trailing and forward P/E were 34.68 and 21.28 respectively according to Yahoo […]
A number of stocks fell in the afternoon session after a stronger-than-expected jobs report signaled that the Federal Reserve may keep interest rates higher for longer.
Veeva Systems (VEEV) fits the "Affordable Growth" strategy with strong earnings growth, reasonable P/E of 20.72, zero debt, and top profitability, offering quality expansion without a sky-high premium.
Veeva Systems (NYSE:VEEV) introduced its new Falcon agentic AI platform, detailing capabilities aimed at clinical, regulatory, safety, and quality workflows. The company outlined early adopter timelines and broadened the rollout of Vault AI agents across its Vault applications. Veeva announced new platform commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery, signaling wider enterprise use of its AI tools. Veeva Systems enters this phase of AI product rollout with...
VEEV lifts its full-year targets and highlights Falcon AI agents after a Q1 beat, with CRM migration wins and the Ostro deal shaping growth.
Recent performance snapshot for Veeva Systems (VEEV) Veeva Systems (VEEV) has seen mixed share performance recently, with the stock roughly flat over the past day, higher over the past week and month, but lower over the past 3 months and year. See our latest analysis for Veeva Systems. At a share price of US$178.60, Veeva Systems has recently seen short term momentum pick up, with a 7 day share price return of 8.65%, even as the 1 year total shareholder return is down 38.40% and longer term...
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 16.3% year on year to $882.9 million. Guidance for next quarter’s revenue was better than expected at $903.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $2.24 per share was 4.9% above analysts’ consensus estimates.
Veeva Systems reports Q1 beat and raises guidance. Analysts maintain Buy ratings and see potential in AI initiatives.
Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:VEEV) with a Neutral and raises the price target from $176 to $190.
Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:VEEV) with a Outperform and lowers the price target from $295 to $270.
Goldman Sachs analyst Gabriela Borges maintains Veeva Systems (NYSE:VEEV) with a Sell and lowers the price target from $190 to $165.
Oppenheimer analyst Ken Wong reiterates Veeva Systems (NYSE:VEEV) with a Outperform and maintains $225 price target.
Stifel analyst David Grossman maintains Veeva Systems (NYSE:VEEV) with a Buy and lowers the price target from $245 to $230.
Evercore ISI Group analyst Kirk Materne maintains Veeva Systems (NYSE:VEEV) with a In-Line and lowers the price target from $240 to $185.
UBS analyst Karl Keirstead maintains Veeva Systems (NYSE:VEEV) with a Neutral and lowers the price target from $220 to $190.
RBC Capital analyst Rishi Jaluria reiterates Veeva Systems (NYSE:VEEV) with a Outperform and maintains $275 price target.
BMO Capital analyst Sean Dodge maintains Veeva Systems (NYSE:VEEV) with a Market Perform and lowers the price target from $220 to $175.
Wells Fargo analyst Stan Berenshteyn maintains Veeva Systems (NYSE:VEEV) with a Overweight and raises the price target from $317 to $320.
Baird analyst Joe Vruwink maintains Veeva Systems (NYSE:VEEV) with a Outperform and raises the price target from $250 to $260.
BTIG analyst David Larsen reiterates Veeva Systems (NYSE:VEEV) with a Buy and maintains $340 price target.
Needham analyst Ryan MacDonald reiterates Veeva Systems (NYSE:VEEV) with a Buy and maintains $270 price target.
Piper Sandler analyst Hannah Rudoff maintains Veeva Systems (NYSE:VEEV) with a Overweight and lowers the price target from $285 to $235.
2026-06-04. The following slide deck was published by Veeva Systems Inc.
Veeva Systems Inc (VEEV) reports strong revenue growth and introduces Veeva Falcon, an AI-driven product set to revolutionize drug development processes.
The biggest insight hiding inside the recent Q1 FY27 earnings report from Veeva Systems (VEEV) is the stark divergence between management's artificial intelligence narrative and the structural realities of its legacy software business. While leadership dedicated significant time to detailing the launch of Veeva Falcon for agentic labor and the Ostro acquisition, the underlying financial tension centers entirely on the forced migration of its CRM customer base.
Veeva Systems beats Q1 earnings and revenue estimates, raises fiscal 2027 guidance, and expands AI offerings as adoption of its software platforms expands.
Gunnar Hansen: Good afternoon, and welcome to Veeva's Fiscal 2027 First Quarter Earnings Conference Call for the quarter ended April 30, 2026. As a reminder, we posted prepared remarks on Veeva's Investor Relations website just after 1:00 p.m. Pacific today. Today's call will be used primarily for Q&A. With me today for Q&A are Peter Gassner, our Chief Executive Officer; Paul Shawah, EVP, Strategy; and Brian Van Wagener, our Chief Financial Officer.
Veeva Systems Inc Class A (NYSE:VEEV) reported stronger-than-expected first-quarter results and lifted its outlook for the remainder of the fiscal year, highlighting continued growth across its software and services businesses as well as increasing traction in artificial intelligence initiatives. The life sciences software provider posted adjusted earnings per share of $2.
Canaccord Genuity analyst David Hynes maintains Veeva Systems (NYSE:VEEV) with a Hold and lowers the price target from $235 to $220.
Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended April 30, 2026.
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 16.3% year on year to $882.9 million. Guidance for next quarter’s revenue was better than expected at $903.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $2.24 per share was 4.9% above analysts’ consensus estimates.
Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call June 3, 2026 5:00 PM EDTCompany ParticipantsGunnar Hansen - Director of Investor RelationsPeter Gassner -...
Veeva Systems (NYSE:VEEV) reported a strong start to the year, with Chief Executive Officer and Co-Founder Peter Gassner saying the company delivered results ahead of guidance as it expands its focus on artificial intelligence for the life sciences industry. On the earnings call, Gassner said total
Investing.com -- Veeva Systems Inc Class A (NYSE:VEEV) reported first-quarter results that exceeded analyst expectations, with adjusted earnings per share of $2.24 beating the consensus estimate of $2.14 by $0.10. Revenue reached $882.9 million, surpassing the $857.75 million estimate and marking a 16% increase from $759.0 million in the same quarter last year.
Veeva Systems beat Q1 2027 estimates with $882.9M revenue and $2.24 EPS, yet stock fell 4.3% on cautious outlook and profit-taking after recent gains.
The headline numbers for Veeva (VEEV) give insight into how the company performed in the quarter ended April 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 7.4% in the afternoon session after the company unveiled Falcon, a new artificial intelligence platform for drug development, and announced several major global customer commitments.
Life sciences cloud software provider Veeva Systems (NYSE:VEEV) will be announcing earnings results this Wednesday after market hours. Here’s what investors should know.
Veeva is on the verge of a technical breakout. The beaten-down biopharma software firm's growth outlook is strong, and it's a cash cow with a stellar balance sheet.
In recent days, Veeva Systems announced a string of major wins, including Kindeva Drug Delivery adopting Veeva Quality Cloud and Merck KGaA and Teva Pharmaceuticals committing globally to Veeva Vault CRM to unify quality and commercial operations. Together with the launch of its new Veeva Falcon agentic platform for drug development, these moves highlight Veeva’s push to embed specialized AI and cloud tools deeper into life sciences workflows. We’ll now examine how Veeva’s deeper integration...
Veeva Systems enters this update cycle with no changes to its existing price targets, which keeps the current analyst baseline intact for now. While there is no new analyst commentary to interpret, the absence of revisions can still tell you something about how expectations are holding steady. Read on to see how to track these kinds of quiet shifts so you can stay on top of the evolving narrative around the stock. Stay updated as the Fair Value for Veeva Systems shifts by adding it to your...
Veeva Systems Inc. (NYSE:VEEV) is one of the Best Wide Moat Stocks to Buy According to Wall Street Analysts. On May 28, the company announced that Kindeva is adopting Veeva Quality Cloud in a bid to modernize its manufacturing operations. This will help bring together the global network of sites onto the single cloud platform. With Veeva QualityDocs, Veeva QMS, Veeva […]
VEEV and IQV are benefiting from life sciences digitization trends, but differences in growth, AI adoption and valuation set them apart.
Get a deeper insight into the potential performance of Veeva (VEEV) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Veeva faces a critical Q1 earnings report after a 29% YTD share decline, with growth stabilization and AI progress in focus. See why VEEV stock is a Hold.
Veeva Systems (NYSE: VEEV) today announced Kindeva is adopting Veeva Quality Cloud to modernize its manufacturing operations, bringing together its global network of sites onto a single cloud platform. With Veeva QualityDocs, Veeva QMS, Veeva Training, and Veeva LearnGxP, Kindeva is building a scalable technology foundation that can meet new customer requirements as the business continues its growth trajectory.
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva Systems (NYSE: VEEV) today announced Veeva Falcon, an agentic platform and standard agents for life sciences' major drug development processes. Falcon works with Veeva Development Cloud applications in clinical, regulatory, and safety to reduce cost, increase speed, and maintain compliance for biopharmas of all sizes. The initial focus areas are trial master file document intake and quality control, health authority correspondence in regulatory, and safety case triage and intake.
